Format

Send to

Choose Destination
Indian J Dermatol Venereol Leprol. 2018 Jun 27. doi: 10.4103/ijdvl.IJDVL_519_17. [Epub ahead of print]

Evaluation of efficacy and safety of intralesional bleomycin in the treatment of common warts: Results of a pilot study.

Author information

1
Department of Dermatology, Venereology and Leprosy, Dr. R. P. Government Medical College, Kangra, Himachal Pradesh, India.

Abstract

Background:

This study evaluated the efficacy and safety of intralesional bleomycin in the treatment of common warts in 50 (32 men, 18 women) patients aged between 14 and 80 (mean ± SD, 28.5 ± 13.27) years.

Methods:

The warts were present over dorsal hands, feet, palms, soles and periungual skin for 1 month to 10 years. They were infiltrated with bleomycin (1 mg/ml) till blanching. The total cumulative dose did not exceed 2 mg in one session. The treatment was repeated after paring of eschar at 2 weeks in case there was no or partial response. The patients were reviewed at 4, 12 and 24 weeks for cure, adverse effects or recurrences and outcome satisfaction levels.

Results:

Complete cure without recurrence occurred in 40 (80%) patients and partial response occurred in 7 (14%) patients at the end of the 24-week study period. Three patients did not complete follow-up. No major systemic or local adverse effects other than injection site pain for 2-3 days were noted. All cured patients were very satisfied (Likert scale 5).

Conclusion:

Intralesional bleomycin appears to be an effective and safe treatment for common warts including palmoplantar and periungual warts. It carries the advantage of low dose, no significant adverse effects and high patient satisfaction. Small number of patients, lack of a control group, comparing different bleomycin concentrations and a short follow-up are a few limitations of this study. Better designed studies are warranted for this useful treatment modality.

KEYWORDS:

Bleomycin; human papilloma virus; verrucae; warts

PMID:
29956682
DOI:
10.4103/ijdvl.IJDVL_519_17
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center